S84762 |
STAT5-IN-1 |
源葉(MedMol) | 98% |
- 提示:詳情請(qǐng)下載說(shuō)明書(shū)。
- 產(chǎn)品描述: STAT5-IN-1 是一種有效的選擇性 STAT5 抑制劑,其對(duì)于STAT5β亞型的IC50值為47 μM
- 靶點(diǎn): STAT5β(Cell-free assay):47 μM;STAT
- 體外研究:
STAT5-IN-1, the STAT5 phosphorylation specific inhibitor, selectively blocks the STAT5 signaling and decreases the percentage of CD4+CD25+Foxp3+ Tregs after SEC2 stimulation on murine splenocytes
- 體內(nèi)研究:
STAT5-IN-1, a STAT5 inhibitor, significantly attenuates atherosclerosis in ApoE-/- mice induced by HFD via decreasing inflammation.
- 細(xì)胞實(shí)驗(yàn): Cell lines: murine splenocytes Concentrations: 0.47 mM Incubation Time: 3 days Method: Fresh murine splenocytes seeded in 24-well flat-bottom plates are treated with each inhibitor at final concentrations of 10 μM LY294002, 10 mM Trigonelline, 0.47 mM STAT5-IN-1, 50 μM SB431542, and 1 μM SIS3, or treated with 10 μg/mL anti-IL-2 neutralizing antibody, respectively, then cells are stimulated with 104 ng/mL SEC2 for 3 days in a humidified incubator at 37 ℃ with 5% CO2.
- 動(dòng)物實(shí)驗(yàn): Animal Models: ApoE-/- mice Dosages: 10 mg/kg Administration: p.o.
- 參考文獻(xiàn):
1. Müller J, et al. Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem. 2008 Mar 25;9(5):723-7. 2. Li Y, et al. Induction of CD4+ regulatory T cells by stimulation with Staphylococcal Enterotoxin C2 through different signaling pathways. Biomed Pharmacother. 2021 Nov;143:112204. 3. Wang X, et al. STAT5 inhibitor attenuates atherosclerosis via inhibition of inflammation: the role of STAT5 in atherosclerosis. Am J Transl Res. 2021;13(3):1422-1431.
- 溶解性: Soluble in DMSO
- 保存條件: -20℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 3.41 ml 17.049 ml 34.097 ml 5 mM 0.682 ml 3.41 ml 6.819 ml 10 mM 0.341 ml 1.705 ml 3.41 ml 50 mM 0.068 ml 0.341 ml 0.682 ml
- 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):
本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:
質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)